Bessemer Group
SCLN

Bessemer Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Bessemer Group’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-305
Closed -$3K – 1976
2017
Q1 		$3K Hold
305
– – ﹤0.01% 1666
2016
Q4 		$3K Buy
+305
New +$3.05K ﹤0.01% 1834

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bessemer Group's SCLN Position: Q2 2017 in Review

Bessemer Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2017, closing a stake of 305 shares — an estimated $3K sold.

Bessemer Group first reported a position in SCLN in Q4 2016 and held it in 2 quarters. The position peaked at $3K in Q1 2017. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

  • Bessemer Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Bessemer Group sold 305 Sciclone Pharmaceuticals Inc shares in Q2 2017, an estimated $3K.
  • Bessemer Group first reported a position in Sciclone Pharmaceuticals Inc in Q4 2016 and held it in 2 quarters.
  • Bessemer Group's Sciclone Pharmaceuticals Inc position peaked at $3K in Q1 2017.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2017.

Based on Bessemer Group's 13F filing for Q2 2017, filed 28 Jul 2017.